Home Cart Sign in  
Chemical Structure| 1207253-08-4 Chemical Structure| 1207253-08-4

Structure of MK-1064
CAS No.: 1207253-08-4

Chemical Structure| 1207253-08-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MK-1064 is a selective orexin 2 receptor antagonist(2-SORA) for the research of insomnia.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MK-1064

CAS No. :1207253-08-4
Formula : C24H20ClN5O3
M.W : 461.90
SMILES Code : O=C(C1=CC(C2=CC(Cl)=CN=C2)=CN=C1C3=NC=CC=C3)NCC4=NC(OC)=C(OC)C=C4
MDL No. :MFCD28502027
InChI Key :CKTWQGHVNRYNCM-UHFFFAOYSA-N
Pubchem ID :44633765

Safety of MK-1064

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
MK-1064 serves as a specific, orally effective OX2R antagonist, with a Ki of 0.5 nM and an IC50 of 18 nM, and is observed to facilitate sleep in live models, suggesting its potential for insomnia research[1].[3].

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice RTg4510 transgenic mouse model Oral gavage 30 mg/kg Single dose, observed for 23 hours To assess the sleep/wake response of rTg4510 mice to MK-1064, results showed MK-1064 significantly reduced wake time and increased NREM and total sleep time, with a more sustained effect in male rTg4510 mice Br J Pharmacol. 2022 Jul;179(13):3403-3417
Mice Stress-Alternatives Model (SAM) Intracerebroventricular injection 0.3 nmol Single administration MK-1064 (Orx 2 receptor antagonist) reduced escape behavior, increased anxious and depressive behaviors, and elevated plasma corticosterone levels. Neuropharmacology. 2018 Dec;143:79-94
Female rhesus monkeys Actigraphy-based sleep parameters model Oral 1, 3 or 10 mg/kg Single administration, with continuous monitoring of sleep parameters To evaluate the effect of MK-1064 on methamphetamine-induced sleep impairments, results showed that MK-1064 dose-dependently improved actigraphy-based sleep parameters. Drug Alcohol Depend. 2024 Jun 1;259:111285
Mice, rats, dogs, and humans Wild-type and OX2R knockout mice, Sprague-Dawley rats, beagle dogs Oral Mice 30 mg/kg, rats 5, 10, 20 mg/kg, dogs 1, 20 mg/kg, humans 5-250 mg Single dose Evaluate the sleep-promoting effects of MK-1064 in various species, showing significant increases in NREM and REM sleep time Sci Rep. 2016 Jun 3;6:27147
Rats Acute and repeated restraint stress model Oral 30 mg/kg Once daily for five days To evaluate the effect of MK-1064 on the HPA axis response to acute and repeated stress. Results showed that MK-1064 pretreatment reduced day 1 ACTH levels but did not further promote habituation on day 5, indicating that endogenous OX2R activity plays a role in acute stress but not in habituation to repeated stress. However, in restrained rats with further stimulated orexins by DREADDs, MK-1064 decreased ACTH levels on day 5. Neuroscience. 2017 Apr 21;348:313-323
Female Wistar rats Adolescent intermittent ethanol exposure model Oral gavage 10 mg/kg and 20 mg/kg Single administration, testing started 60 minutes after administration To test the effects of MK-1064 on sleep pathology and waking event-related oscillations. Results showed that MK-1064 hastened SWS onset and increased the number of SWS episodes, without increasing sleep fragmentation in AIE and controls. Additionally, MK-1064 increased waking ERO energy in delta, theta, and beta frequency bands. Alcohol Clin Exp Res. 2020 Jul;44(7):1378-1388

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.16mL

0.43mL

0.22mL

10.82mL

2.16mL

1.08mL

21.65mL

4.33mL

2.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories